1. Khatana S.A.M., Groeneveld P.W. Health disparities and the coronavirus disease 2019 (COVID-19) pandemic in the USA. J Gen Intern Med. 2020; 35 (8): 2431–2. DOI: https://doi.org/10.1007/s11606-020-05916-w
2. Bragina A.V., Pilipenko D.V., Akhmadeev D.R. Impact of COVID-19 and the crisis caused by it on the Russian economy. E-Scio. 2020; (8): 9–15. (in Russian)
3. Borisevich S.V., Sizikova T.E., Lebedev V.N. COVID-19 Pandemic: analysis of possible scenarios for the development of the epidemic in Russia. Vestnik voysk RKhB zashchity [Bulletin of the RKhB Protection Troops]. 2020; 4 (2): 116–30. DOI: https://doi.org/10.35825/2587-5728-2020-4-2-116-130 (in Russian)
4. Budarin S.S. Sustainability of global health systems during the COVID-19 pandemic. Ekonomika i upravlenie: problemy, resheniya [Economics and Management: Problems, Solutions]. 2020; 3 [8 (104)]: 105–14. DOI: https://doi.org/10.34684/ek.up.p.r.2020.08.03.013 (in Russian)
5. Nikitin I.G., Melekhov A.V., Sayfullin M.A., Agafonov S.S., Bedritsky S.A., Vishninsky A.A., et al. Organizing the medical care for the COVID-19 patients in non-infectious Moscow hospital: reassignment experience. Terapevticheskiy arkhiv [Therapeutic Archive]. 2020; 92 (11): 31–7. DOI: https://doi.org/10.26442/00403660.2020.11.000838 (in Russian)
6. Li G., Ruan S., Zhao X., Liu Q., Dou Y., Mao F. Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses. Comput Struct Biotechnol J. 2021; 19: 1–15. DOI: https://doi.org/10.1016/j.csbj.2020.11.056
7. Tripathi N., Tripathi N., Goshisht M.K. COVID-19: inflammatory responses, structure-based drug design and potential therapeutics. Mol Divers. 2021; Jan 5: 1–17. DOI: https://doi.org/10.1007/s11030-020-10176-1
8. Kotenko O.N., Vinogradov V.E., Dorofeeva E.G., Vasina N.V., Ivanova E.S., Berdinsky V.A., et al. Organization of outpatient care after organ transplantation during the pandemic of the new coronavirus infection COVID-19 in Moscow. Vestnik transplantologii i iskusstvennykh organov [Bulletin of Transplantology and Artificial Organs]. 2020; 22 (S): 174–5. (in Russian)
9. Golukhova E.Z., Slivneva I.V., Rybka M.M., Mamalyga M.L., Alekhin M.N., Klyuchnikov I.V., et al. Pulmonary hypertension as a risk assessment factor for unfavorable outcome in patients with COVID-19. Rossiiskii kardiologicheskii zhurnal. 2020; 25 (12): 121–33. DOI: https:// doi.org/10.15829/1560-4071-2020-4136 (in Russian)
10. Alcocer-Díaz-Barreiro L., Cossio-Aranda J., Verdejo-Paris J., Odinde-Los-Ríos M., Galván-Oseguera H., Álvarez-López H., et al. COVID-19 and the renin, angiotensin, aldosterone system. A complex relationship. Arch Cardiol Mex. 2020; 90 (suppl): 19–25. DOI: https://doi.org/10.24875/ ACM.M20000063
11. Samsonova M.V., Mikhaleva L.M., Zairat’yants O.V., Varyasin V.V., Bykanova A.V., Mishnev O.D., et al. Lung Pathology of COVID-19 in Moscow. Arkhiv patologii [Archive of Pathology]. 2020; 82 (4): 32–40. DOI: https:// doi.org/10.17116/patol20208204132 (in Russian)
12. Svistunov A.A., Khorobrykh T.V., Makhnach G.K., Krylov A.Yu., Bunina D.V., Volgin M.V., et al. Experience of immunomodulators use for prevention of COVID-19 infection among health care personnel and avoidance of COVID-induced pneumonia complications in patients with СОVID-19. Terapiya [Therapy]. 2020; 6 [7 (41)]: 156–64. DOI: https://doi. org/10.18565/therapy.2020.7.156-164 (in Russian)
13. Kolbin A.S. An early assessment of the efficacy of medicines in the treatment of patients with COVID-19. Infektsiya i immunitet [Infection and Immunity]. 2020; 10 (2): 277–86. DOI: https://doi.org/10.15789/2220-7619-AEA-1458 (in Russian).
14. Vechorko V.I., Silaev B.V., Tan’shina O.V., Zhenina E.A. Preparation and results of work in a multi -specialty hospital in the context of the COVID-19 pandemic. Byulleten’ natsional’nogo nauchno-issledovatel’skogo instituta obshchestvennogo zdorov’ya imeni N.A. Semashko [Bulletin of the National Research Institute of Public Health named after N.A. Semashko]. 2020; (4): 46–51. DOI: https://doi.org/10.25742/NRIPH.2020.04.006 (in Russian)
15. Zakharova E.G., Vechorko V.I., Zhenina E.A., Gumenyuk S.A. Experience of reprofiling the reception department of a multi-disciplinary hospital under the conditions of the COVID-19 epidemic. Profilakticheskaya meditsina [Preventive Medicine]. 2020; 23 (8): 14–8. DOI: https://doi. org/10.17116/profmed20202308114 (in Russian)
16. Dondorp A.M., Hayat M., Aryal D., Beane A., Schultz M.J. Respiratory support in COVID-19 patients, with a focus on resource-limited settings. Am J Trop Med Hyg. 2020; 102 (6): 1191–7. DOI: https://doi.org/10.4269/ ajtmh.20-0283
17. Gubkin A.V., Shaburov R.I., Cheremushkin S.V., Latypov R.S., Rybina O.V., Ataulakhanov F.I. Features of diagnostics and treatment of dic syndrome in patients with COVID-19. Gematologiya. Transfuziologiya. Vostochnaya Evropa [Hematology. Transfusiology. Eastern Europe]. 2021; 7 (1): 90–7. DOI: https://doi.org/10.34883/PI.2021.7.1.008 (in Russian)
18. Zhukova O.V., Khokhlov A.L. Clinical and economic constituents of the application of dexamethasone and tocilizumab in the therapy for severe conditions in patients with COVID-19. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya [Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology]. 2021; 14 (1): 16–27. DOI: https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.060 (in Russian)
19. Potere N., Batticciotto A., Vecchié A., et al. The role of IL-6 and IL-6 blockade in COVID-19. Expert Rev Clin Immunol. 2021. May 27. P. 1–17. DOI: https://doi.org/10.1080/1744666X.2021.1919086
20. Chen L.Y.C., Biggs C.M., Jamal S., et al. Soluble interleukin-6 receptor in the COVID-19 cytokine storm syndrome. Cell Rep Med. 2021; Apr 19: 100269. DOI: https://doi.org/10.1016/j.xcrm.2021.100269
21. McElvaney O.J., Curley G.F., Rose-John S., et al. Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respir Med. 2021; Apr 16: S2213-2600(21)00103-X. DOI: https://doi. org/10.1016/S2213-2600(21)00103-X
22. Angriman F., Ferreyro B.L., Burry L., et al. Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context. Lancet Respir Med. 2021; Apr 27: S2213-2600(21)00139-9. DOI: https:// doi.org/10.1016/S2213-2600(21)00139-9
23. Flisiak R., Jaroszewicz J., Rogalska M., et al. Tocilizumab improves the prognosis of COVID-19 in patients with high IL-6. J Clin Med. 2021; 10 (8): 1583. DOI: https://doi.org/10.3390/jcm10081583
24. Meanwatthana J., Majam T. Interleukin-6 antagonists: lessons from cytokine release syndrome to the therapeutic application in severe COVID-19 infection. J Pharm Pract. 2021; Mar 24: 8971900211000691. DOI: https://doi.org/10.1177/08971900211000691
25. Tleyjeh I.M., Kashour Z., Riaz M. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis: first update. Clin Microbiol Infect. 2021; Apr 26: S1198-743X(21)00204-4. DOI: https://doi.org/10.1016/j.cmi.2021.04.019
26. Klopfenstein T., Gendrin V., Kadiane-Oussou J. Tocilizumab in COVID-19 pneumonia: practical proposals based on a narrative review of randomised trials. Rev Med Virol. 2021; Apr 21: e2239. DOI: https://doi. org/10.1002/rmv.2239
27. Mehta M., Purpura L.J., McConville T.H., et al. What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak. PLoS One. 2021; 16 (4): e0249349. DOI: https://doi. org/10.1371/journal.pone.0249349
28. Ascierto P.A., Fu B., Wei H. IL-6 modulation for COVID-19: the right patients at the right time? J Immunother Cancer. 2021; 9 (4): e002285. DOI: https://doi.org/10.1136/jitc-2020-002285
29. Keragala C.B., Medcalf R.L., Myles P.S., et al. Fibrinolysis and COVID-19: a tale of two sites? J Thromb Haemost. 2020; 18 (9): 2430–2. DOI: https://doi.org/10.1111/jth.15017
30. Medcalf R.L., Keragala C.B., Myles P.S. Fibrinolysisand COVID-19: a plasminparadox. J Thromb Haemost. 2020; 18: 2118–22. DOI: https:// doi.org/10.1111/jth.14960
31. Tang N., Bai H., Xiong D., Sun Z. Specific coagulation markers may provide more therapeutic targets in COVID-19 patients receiving prophylactic anticoagulant. J Thromb Haemost. 2020; 18 (9): 2428–30. DOI: https://doi.org/10.1111/jth.14988
32. Bachler M., Bösch J., Stürzel D.P., et al. Impaired fibrinolysis in critically ill COVID-19 patients. Br J Anaesth. 2021; 126 (3): 590–8. DOI: https://doi.org/10.1016/j.bja.2020.12.010